Roswell Park Cancer Institute secured FDA approval for an early phase I clinical study of a possible lung cancer vaccine developed in Cuba, Roswell CEO Dr. Candace Johnson announced today.

This is a first for an institution in this country, Johnson said.

The clinical trial of CIMIvax involving 60 to 90 patients with advanced lung cancer will start in about 30 days.

Johnson called CIMIvax “an incredibly innovative immunotherapy for lung cancer that was developed in Cuba” and a “significant first.” “This is historic, the first time in the modern era that a Cuban and an American institution have been allowed to come together to create this joint company and venture,” she said.  See more at … Roswell Park gets OK for trial of lung cancer vaccine